Welcome to our dedicated page for Ludwig Enter news (Ticker: LUDG), a resource for investors and traders seeking the latest updates and insights on Ludwig Enter stock.
Ludwig Enterprises, Inc. (LUDG) delivers cutting-edge solutions at the intersection of mRNA genomics and artificial intelligence. This news hub provides investors and healthcare professionals with essential updates on the company's non-invasive diagnostic innovations, strategic partnerships, and clinical research developments.
Access real-time updates on FDA submissions, intellectual property milestones, and Revealia™ cancer screening enhancements. Our curated news collection covers earnings announcements, preclinical study results, and AI algorithm advancements that power the company's proprietary inflammatory index.
Key focus areas include mRNA biomarker discoveries, machine learning model refinements, and collaborations with leading medical institutions. Track progress in early detection technologies for chronic inflammation-related diseases, including breast cancer and cardiovascular conditions.
Bookmark this page for streamlined access to Ludwig's regulatory filings, executive commentary, and peer-reviewed research findings. Subscribe to our alerts for immediate notifications about material developments in this dynamic biotechnology sector.
Ludwig Enterprises (LUDG) has published an abstract on the ASCO website detailing a novel breast cancer screening method that analyzes mRNA from non-invasively collected buccal (cheek) cells combined with machine learning algorithms. The study, conducted across 40 U.S. clinical centers, developed a custom microarray chip analyzing 48 mRNA-based cytokine biomarkers.
The research identified two high-performing six-biomarker combinations, achieving impressive metrics with F-scores ≥0.85. The first system achieved precision of 0.892, recall of 0.913, and an AUC of 0.897, while the second system showed precision of 0.888, recall of 0.902, and an AUC of 0.849. These results suggest potential clinical utility for early breast cancer detection using this non-invasive screening approach.
Ludwig Enterprises (OTC:LUDG) has announced the development of Revealia Breast™, a non-invasive breast cancer screening test expected to launch in Q3 2025. The test uses a simple cheek swab to detect cancer-related inflammation through mRNA biomarker analysis and AI technology, potentially identifying breast cancer before physical symptoms appear.
Recent data from the American Society of Breast Surgeons shows that early detection through multidisciplinary breast cancer clinics resulted in 39.7% of cases showing non-invasive disease, compared to 13.2% in traditional management. Revealia Breast™ aims to provide more affordable, accessible, and comfortable screening than mammograms, particularly beneficial for women with dense breast tissue where mammograms may miss early signs.
The test is part of Ludwig's broader pipeline targeting major cancers, with the global breast cancer screening market valued at over $4 billion. The company plans to submit additional clinical validation papers and announce new scientific advisory board members this quarter.
Ludwig Enterprises has achieved a significant milestone with two abstracts accepted for publication in the prestigious Journal of Clinical Oncology. The abstracts focus on their innovative mRNA cancer screening program, specifically addressing breast cancer detection through non-invasive methods.
The accepted abstracts are titled "Non-invasively Collected Buccal Cell mRNA Reveals Novel Breast Cancer Signal" and "A Novel Machine Learning Approach to Breast Cancer Screening Using Non-invasive mRNA Collection." The company's scientific team, led by CSO Marvin S. Hausman MD, will present at the ASCO 2025 Annual Meeting in Chicago from May 30th to June 3rd.
This presentation opportunity at ASCO will allow Ludwig to showcase their proprietary cancer diagnostic technology to major laboratory, telehealth, and pharmaceutical companies. The company plans to highlight their upcoming launch of a noninvasive cheek cell breast cancer test, positioning it as a potential game-changing development in cancer diagnostics.
Ludwig Enterprises (LUDG) has appointed Charles T. Todd, Jr. as CEO and Chairman of the Board to lead the company's transformation from a research and diagnostic development business to a healthcare solutions provider. Todd brings over 40 years of experience in the Clinical Laboratory Industry, notably founding the first cancer specialty laboratory in the US.
Todd's previous achievements include his 20-year tenure at BioReference Laboratories, where he served as Executive Vice President and led the company's growth to become the third-largest clinical laboratory in the United States. BioReference was ultimately sold to OPKO Health for $1.2 billion in 2015.
The company is developing a patent-pending cancer screening technology utilizing 48 mRNA markers, nanoscale detection, and AI to provide non-invasive early detection through cheek swab testing, particularly focusing on breast cancer screening.
Ludwig Enterprises (OTC PINK:LUDG) has initiated the PCR validation test process for its breast cancer screening program, Revealia™. The company has engaged an independent Florida laboratory for third-party validation of their PCR-based screening technology. The validation process, typically taking 6-8 weeks, is being expedited to 5-6 weeks, targeting a Q4 2024 launch. The screening panel utilizes PCR evaluation of 6 mRNA biomarkers to enhance sensitivity and predictability in breast cancer detection.
Ludwig Enterprises (OTC PINK:LUDG) has filed a provisional patent for a novel cancer detection method called 'mRNAs Differentially Expressed in Cancer.' The breakthrough technology uses a six-mRNA gene combination that shows enhanced sensitivity and specificity in breast cancer detection. The development is based on research involving over 3,300 cheek cell samples from 40 U.S. medical centers, where AI analyzed more than 12 million combinations of a 48-gene mRNA microarray. The company plans to rebrand as Revealia™ in 2024, subject to regulatory approvals.
Ludwig Enterprises (OTC PINK:LUDG) announces Revealia™, a revolutionary AI-powered cancer screening technology. This mail-order, non-invasive cheek swab test aims to detect early signs of cancer using advanced artificial intelligence and machine learning.
The core of Revealia™ is the Revealia Inflammatory Index (RII), which quantifies cancer risk by analyzing mRNA-based genetic signals. The AI technology continuously improves its accuracy by learning from an expanding dataset collected from over 40 multipurpose medical clinics across the United States.
Key features of the AI approach include optimizing sensitivity and specificity trade-offs and continuous learning. Dr. Marvin S. Hausman, CSO, and Kyle Ambert, a member of Ludwig's Scientific Advisory Board, highlight the potential of this technology to revolutionize early cancer detection and screening.
Ludwig Enterprises Inc. (OTC PINK:LUDG) has announced Revealia™, an AI-powered cancer screening technology. This revolutionary mail-order non-invasive cheek swab test aims to transform early cancer detection with continuously improving accuracy. At its core is the Revealia Inflammatory Index (RII), which uses advanced AI to analyze mRNA-based genetic signals associated with cancer presence.
Developed by Dr. Kyle Ambert, PhD, Director of Data Science at Nike's Consumer Data Science Division, the AI technology employs machine learning algorithms that continuously update and improve as new patient data is received. Key features include optimization of sensitivity and specificity trade-offs, continuous learning from an expanding dataset, and analysis of mRNA samples from over 40 multipurpose medical clinics across the United States.
Ludwig Enterprises (OTC PINK:LUDG) has acquired intellectual property and patents for mRNA Neuro Panel and Serotonin Assay, including accumulated test data. This acquisition enables the use of mRNA genetic biomarkers to study brain inflammation in diseases like autism, PTSD, Parkinson's, and Alzheimer's. The company has also acquired breakthrough technology for measuring serotonin levels in salivary exosomes. The acquisition includes a U.S. Patent Application, international publication, serotonin assays developed at the University of Central Florida, and work product from Autism Spectrum Disorder and Fragile X Syndrome studies. Ludwig plans to start its screening business with breast cancer and expand to other diseases.
Nova Mentis Life Science Corp. (NMLSF) has entered into an intellectual property conveyance agreement with Ludwig Enterprises Inc. and Dr. Marvin S. Hausman. NOVA will assign its mRNA Neuro Panel and Serotonin Assay intellectual property to Ludwig. In exchange, Hausman will forgive NOVA's $245,712 debt, and Ludwig will issue 750,000 restricted common shares to NOVA. Additionally, NOVA will receive a 10-year royalty of 2.5% on revenue up to $245,712 and 5% thereafter from the Property's commercialization.
NOVA's Health Canada Phase 2a clinical trial for Fragile X Syndrome has faced recruitment challenges, with no candidates meeting enrollment requirements. The company's Board is actively seeking new business opportunities in the Life Sciences sector to create shareholder value.
FAQ
What is the current stock price of Ludwig Enter (LUDG)?
What is the market cap of Ludwig Enter (LUDG)?
